These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 37793784)

  • 1. Cytochrome P450 Enzymes as Drug Targets in Human Disease.
    Guengerich FP
    Drug Metab Dispos; 2024 May; 52(6):493-497. PubMed ID: 37793784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cloning and tissue expression of cytochrome P450 2S1, 4V2, 7A1, 7B1, 8B1, 24A1, 26A1, 26C1, 27A1, 39A1, and 51A1 in marmosets.
    Uehara S; Uno Y; Inoue T; Sasaki E; Yamazaki H
    Drug Metab Pharmacokinet; 2020 Apr; 35(2):244-247. PubMed ID: 31980379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytochrome
    Kim D; Kim V; Tateishi Y; Guengerich FP
    Drug Metab Dispos; 2021 Oct; 49(10):902-909. PubMed ID: 34330716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human cytochrome P450 enzymes 5-51 as targets of drugs and natural and environmental compounds: mechanisms, induction, and inhibition - toxic effects and benefits.
    Rendic SP; Peter Guengerich F
    Drug Metab Rev; 2018 Aug; 50(3):256-342. PubMed ID: 30717606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human cytochrome P450 enzymes bind drugs and other substrates mainly through conformational-selection modes.
    Guengerich FP; Wilkey CJ; Phan TTN
    J Biol Chem; 2019 Jul; 294(28):10928-10941. PubMed ID: 31147443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetic analysis of the activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone by heterologously expressed human P450 enzymes and the effect of P450-specific chemical inhibitors on this activation in human liver microsomes.
    Patten CJ; Smith TJ; Murphy SE; Wang MH; Lee J; Tynes RE; Koch P; Yang CS
    Arch Biochem Biophys; 1996 Sep; 333(1):127-38. PubMed ID: 8806763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of aromatase inhibitors in boys with short stature: what to know before prescribing?
    Linardi A; Damiani D; Longui CA
    Arch Endocrinol Metab; 2017; 61(4):391-397. PubMed ID: 28977209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A suite of activity-based probes for human cytochrome P450 enzymes.
    Wright AT; Song JD; Cravatt BF
    J Am Chem Soc; 2009 Aug; 131(30):10692-700. PubMed ID: 19583257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro cytochrome P450-mediated metabolism of exemestane.
    Kamdem LK; Flockhart DA; Desta Z
    Drug Metab Dispos; 2011 Jan; 39(1):98-105. PubMed ID: 20876785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-step oxidations catalyzed by cytochrome P450 enzymes: Processive vs. distributive kinetics and the issue of carbonyl oxidation in chemical mechanisms.
    Guengerich FP; Sohl CD; Chowdhury G
    Arch Biochem Biophys; 2011 Mar; 507(1):126-34. PubMed ID: 20804723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intersection of the Roles of Cytochrome P450 Enzymes with Xenobiotic and Endogenous Substrates: Relevance to Toxicity and Drug Interactions.
    Guengerich FP
    Chem Res Toxicol; 2017 Jan; 30(1):2-12. PubMed ID: 27472660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reaction Phenotyping of Low-Turnover Compounds in Long-Term Hepatocyte Cultures Through Persistent Selective Inhibition of Cytochromes P450.
    Smith S; Lyman M; Ma B; Tweedie D; Menzel K
    Drug Metab Dispos; 2021 Nov; 49(11):995-1002. PubMed ID: 34407991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Catalytic modulation of human cytochromes P450 17A1 and P450 11B2 by phospholipid.
    Peng HM; Barlow C; Auchus RJ
    J Steroid Biochem Mol Biol; 2018 Jul; 181():63-72. PubMed ID: 29548669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4'-methanol-bisbenzonitrile in vitro.
    Jeong S; Woo MM; Flockhart DA; Desta Z
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):867-75. PubMed ID: 19198839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR.
    Nishimura M; Yaguti H; Yoshitsugu H; Naito S; Satoh T
    Yakugaku Zasshi; 2003 May; 123(5):369-75. PubMed ID: 12772594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of 17α,20-Lyase and New Hydroxylation Reactions of Human Cytochrome P450 17A1: 18O LABELING AND OXYGEN SURROGATE EVIDENCE FOR A ROLE OF A PERFERRYL OXYGEN.
    Yoshimoto FK; Gonzalez E; Auchus RJ; Guengerich FP
    J Biol Chem; 2016 Aug; 291(33):17143-64. PubMed ID: 27339894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selectivity of polycyclic inhibitors for human cytochrome P450s 1A1, 1A2, and 1B1.
    Shimada T; Yamazaki H; Foroozesh M; Hopkins NE; Alworth WL; Guengerich FP
    Chem Res Toxicol; 1998 Sep; 11(9):1048-56. PubMed ID: 9760279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Looking for selectivity among cytochrome P450s inhibitors.
    Cavalli A; Recanatini M
    J Med Chem; 2002 Jan; 45(2):251-4. PubMed ID: 11784128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites.
    Marill J; Cresteil T; Lanotte M; Chabot GG
    Mol Pharmacol; 2000 Dec; 58(6):1341-8. PubMed ID: 11093772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ruthenium-containing P450 inhibitors for dual enzyme inhibition and DNA damage.
    Zamora A; Denning CA; Heidary DK; Wachter E; Nease LA; Ruiz J; Glazer EC
    Dalton Trans; 2017 Feb; 46(7):2165-2173. PubMed ID: 28121322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.